Dosing & Uses
Dosage Forms & Strengths
solution
- 0.5%
- 1%
- 2%
Mydriasis/Cycloplegia Diaganosis
1-2 gtt of 1% solution in eye; may repeat in 5 minutes PRN; cycloplegia & mydriasis may last for 24 hours
Use 2% in heavily pigmented iris
Overdose Management
Ocular: Flush eyes w/water
Ingestion: Emesis, lavage
Severe systemic ADR's: Physostigmine
Dosage Forms & Strengths
solution
- 0.5%
- 1%
- 2%
Mydriasis/Cycloplegia
1-2 gtt of 0.5%, 1% or 2% solution in eye; may repeat 5 minutes later by second application of 0.5% or 1% solution if necessary
Adverse Effects
Frequency Not Defined
Blurred vision
Burning sensation in eye
Light intolerance
Tachycardia
Conjunctivitis
Raised intraocular pressure
Hyperreactive response in Down's syndrome children (atropine)
Drowsiness
Warnings
Contraindications
Hypersensitivity to drug or components
Cautions
Remove contact lenses prior to administration and wait 15 min before reinserting
The elderly may be predisposed to increased intraocular pressure
Mydriatics may produce transient elevation of intraocular pressure; patients with untreated narrow-angle glaucoma or anatomically narrow angles may be susceptible to angle-closure following administration
Dropper tip is not to touch any surface, as this may contaminate the solution
A transient burning sensation may occur upon instillation
Patients should be advised not to drive or engage in other hazardous activities while pupils are dilated
Patients may experience sensitivity to light and should protect eyes in bright illumination during dilation
Parents should be warned not to get this preparation in their child's mouth and to wash their own hands and the child's hands following administration
Feeding intolerance may follow ophthalmic use of this product in infants; it is recommended that feeding be withheld for 4 hours after examination
CNS effects
- May cause central nervous system (CNS) disturbances, especially in younger age groups but may occur at any age, especially with stronger solutions
- Infants are especially prone to CNS and cardiopulmonary side effects; to minimize absorption, use only 1 drop of 0.5% solution per eye, followed by pressure applied over nasolacrimal sac for two to three minutes; observe infants closely for at least 30 minutes following instillation
Pregnancy & Lactation
Pregnancy
Animal reproduction studies have not been conducted; not known whether cyclopentolate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity; administer to a pregnant woman only if clearly needed
Lactation
Not known whether this drug is excreted in human milk; because many drugs are excreted in human milk, exercise caution when drug is administered to a nursing woman
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Onset: rapid; max effect not for 30 min
Excretion: urine
Mechanism of Action
Blocks action of acetylcholine resulting in relaxation of the cholinergically innervated iris sphincter muscle
Cholinergic stimulation of accommodative ciliary muscle of lens is also blocked
Anticholinergic effects of cyclopentolate in eye produce dilation of the pupil (mydriasis) and paralysis of accommodation (cycloplegia)
Pharmacokinetics
Onset of action: 25-75 min (cycloplegia); 30-60 min (mydriasis)
Duration: < 24hr
Absorption: Minimal systemic
Images
BRAND | FORM. | UNIT PRICE | PILL IMAGE |
---|---|---|---|
Cyclogyl ophthalmic (eye) - | 2 % drops | ![]() | |
Cyclogyl ophthalmic (eye) - | 1 % drops | ![]() | |
Cyclogyl ophthalmic (eye) - | 2 % drops | ![]() | |
Cyclogyl ophthalmic (eye) - | 2 % drops | ![]() | |
Cyclogyl ophthalmic (eye) - | 0.5 % drops | ![]() | |
Cyclogyl ophthalmic (eye) - | 1 % drops | ![]() | |
cyclopentolate ophthalmic (eye) - | 1 % drops | ![]() | |
cyclopentolate ophthalmic (eye) - | 2 % drops | ![]() | |
cyclopentolate ophthalmic (eye) - | 2 % drops | ![]() | |
cyclopentolate ophthalmic (eye) - | 1 % drops | ![]() | |
cyclopentolate ophthalmic (eye) - | 1 % drops | ![]() | |
cyclopentolate ophthalmic (eye) - | 2 % drops | ![]() | |
cyclopentolate ophthalmic (eye) - | 0.5 % drops | ![]() | |
cyclopentolate ophthalmic (eye) - | 1 % drops | ![]() | |
cyclopentolate ophthalmic (eye) - | 1 % drops | ![]() | |
cyclopentolate ophthalmic (eye) - | 1 % drops | ![]() |
Copyright © 2010 First DataBank, Inc.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.